Background: While enza and abi have substantially improved outcomes for patients (pts) with mCRPC, de novo and acquired resistance mutations are increasingly recognized. Methods: Pts receiving abi or enza in the course of routine clinical care were consented for blood collection at weeks 0, 4, 8 and 12 of therapy, and at the time of progression (based on Prostate Cancer Working Group 3 [PCGW3] criteria). CellSearch was used for CTC enumeration; individual cells were isolated and subsequently classified for EpCAM and C45 positivity. RNA sequencing (RNA-seq) was performed on pools of up to 10 CTCs. Results: Amongst 36 pts enrolled, median age was 71 (range, 54-84) and median PSA was 21.9 ng/dL (range, 0-918.3). Regarding treatment, 21 pts received abi and 15 received enza. By PCWG3 criteria, 23 pts met the definition of progression on abi or enza. Mean/median CTC count was 158/5 (IQR 25%-75%, 0-15). On RNA-seq of CTCs collected at the time of progression, AR was the most mutated gene followed by ATRX, GNAS, FOXA1, KMT2A and CNOT1. Several deleterious mutations in the DNA damage response genes were noted including frameshift mutations in PRKDC, MSH2 and MLH1. Differential gene expression analysis between abi/enza sensitive and abi/enza resistant samples revealed 2100 differentially regulated genes in drug-resistant CTCs. Ingenuity pathway analysis was used to identify pathways altered due to differential regulation of these genes. Among these pathways, TGFb and CCDN1 signaling were found to be significantly up-regulated in drug resistant CTCs. In vitro enzaresistant models will be presented, offering validation of our clinical findings. Conclusions: RNA-seq of CTCs representing abi/enza sensitive and resistant states can identify potential mechanisms of resistance. Therapies targeting the downstream signaling mediated by CCND1, such as CDK4/6 inhibitors (e.g., palbociclib or ribociclib), could avert resistance. Targeting TGFb, another putative mediator of resistance, may be warranted. Background: Although circulating cell-free DNA (cfDNA) in blood is being touted as a frontier noninvasive approaches, its clinical utility still remains questionable. The purpose of this study was to compare the efficacy of cfDNA by comparing with blood CEA levels and radiological evaluation in patients with unresectable metastatic colorectal cancer (mCRC) during treatment of systemic chemotherapy. Methods: In this study, 12 patients with mCRC who were intended to receiving systemic chemotherapy were enrolled. Methylation status of CpG sites, considered as cancer-specific alteration, and concentration of cfDNA were evaluated from blood plasma obtained before administration of systemic chemotherapy in each treatment cycle. To analyze aberrant cancer-specific methylation, we modified the highly sensitive assay for bisulfite DNA (Hi-SA) followed by fluorescence-based PCR, as reported previously (JNCI 2009). Our modified methodology can detect 8 loci of target promoters, therefore methylation score (MS) could be ranged from 0 to 8 at a given time. Results: Of the 12 patients enrolled, 10 patients experienced radiological progressive disease (PD). Plasma MS was significantly increased before radiological PD in 8 of 10 patients with PD. Thus MS had the median lead time of 73 days (range: 0-231 days) before documentation of radiological PD. In contrast, serum CEA level could predict PD only in the 2 patients before documentation of their radiological PD. Consequently, plasma MS could predict radiological PD with the median lead time of 9 days (range: 0-21 days) compared with serum CEA. We also examined whether cfDNA concentration level in plasma was associated with radiological PD. Of the 12 patients, only 3 patients increased cfDNA concentration level before radiological PD with the median lead time of 88 days (range; 21-140 days). Conclusions: Our circulating cell free DNA-based assay is a robust methodology for capturing DNA methylation in circulating cell-free DNA in plasma, and is useful for the early identification of CRC patients that are at risk of developing PD prior to radiographic documentation. Legal entity responsible for the study: Takeshi Nagasaka Funding: None Disclosure: All authors have declared no conflicts of interest.
1672P ctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRC Background: KRAS mutations predict failure of anti-EGFR therapies, thus genotyping colorectal cancer (CRC) is crucial for personalized treatments. Cancer heterogeneity hamper the assessment of KRAS mutational status in tumor tissues, leading to the search for alternative sources of cancer genetic information. ctDNA of patients treated with anti-EGFR drugs exhibit pulsatile levels of KRAS mutations, revealing that the CRC genome adapts dynamically to intermittent EGFR blockade. These data support the use of liquid biopsy to monitor the molecular underpinnings of resistance to anti-EGFR agents. Research has been selectively concentrated on the emergence of resistant clones in the blood of patients with wtKRAS CRC as biomarker of anti-EGFR therapy resistance. Conversely our group demonstrated that patients with metastatic CRC harboring mutated primary tumors, thus not candidate to EGFR inhibitors, frequently have wtKRAS circulating tumor cells in blood. To explain the prevalence of wtKRAS clones in these patients, the generation of hypoxia has been suggested. We aimed to determine if anti-angiogenic drugs might drive the biological evolution of mKRAS clones towards a prevalent wtKRAS disease, by ctDNA. Methods: Ten patients with histologically confirmed mKRAS mCRC candidate to firstline anti angiogenic drugs were prospectively enrolled. To investigate whether wtKRAS clones emerge as dominant under treatments, serial blood draws were performed at baseline and at 3 months months of treatment. Idylla TM (Biocartis) ctKRAS Mutation Assay was used to track KRAS mutational status in serial ctDNA determinations for each patient. Results: At baseline, KRAS mutational status in ctDNA was found concordant with tumor tissues in all patients analysed. At 3 months,3/10 (30%) of mKRAS CRC patients treated with antiangiogenic drugs switched to wtKRAS ctDNA in peripheral blood. Conclusions: These preliminary data suggest that patients with mKRAS colon cancer not unfrequently switch to a prevalent wtKRAS disease in course of treatment with anti-angiogenic drugs. if confirmed in a large patients population, these results might shift second-line therapeutic options for KRAS mutant mCRC patients from insufficient to promising. Legal entity responsible for the study: Paola Gazzaniga Funding: Merck Disclosure: All authors have declared no conflicts of interest. Background: Esophageal cancer (EC) is the eighth most common cancer in the world. The incident rate of EC is significantly high in Asian countries compared to rest of the world. Circulating tumor cells (CTCs) derived from EC have the potential to be precursors of metastasis. It is therefore of paramount interest to isolate and characterize CTCs from EC patients to monitor and detection of recurrence. The aim of present study is to evaluate drug response using patient-derived CTC cultures obtained from EC.
Methods: Custom microfabricated tapered microwells will be integrated with microfluidics to expand CTC clusters without any prior pre-enrichment. The established CTC cluster assay will be used to screen anticancer drugs. The drug concentrations selected will be centered on the IC50 that had previously established for each drug across EC cell lines. Cluster formation in culture will be correlated with overall patient survival. 50 patients with a proven diagnosis of EC attending the Department of Surgical Oncology, Kidwai Institute of Oncology will be enrolled into the study. 
